Effrx Pharmaceuticals Sa

Effrx Pharmaceuticals Sa company information, Employees & Contact Information

Updated June 2026

Quick answer

Effrx Pharmaceuticals Sa is a Pharmaceutical Manufacturing company. It has approximately 24 employees on record. Contact data was last refreshed in June 2026. Find Effrx Pharmaceuticals Sa's verified employee emails, phone numbers, headquarters address, and key decision makers below.

EffRx Pharmaceuticals is a Swiss commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications. EffRx’s lead commercialized product, Binosto® for the treatment of osteoporosis, is successfully commercialized by Licensees across US, European, Asian and Middle Eastern countries. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients. EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from FDA for a pipeline asset. EffRx is a member of the World Orphan Drug Alliance (WODA - www.woda-alliance.com).

Company Details

Employees
24
Address
Wolleraustrasse 41b, Freienbach,8807,switzerland
Phone
+41 44 503 78 60
Email
in****@****frx.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
effrx.com
HQ
Freienbach
Looking for a particular Effrx Pharmaceuticals Sa employee's phone or email?

Effrx Pharmaceuticals Sa Questions

News

EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States - Business Wire

EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States Business Wire

Abiogen acquires EffRx to fortify bone disease portfolio - Pharmaceutical Technology

Abiogen acquires EffRx to fortify bone disease portfolio Pharmaceutical Technology

Abiogen Pharma acquires majority stake in EffRx - Switzerland Global Enterprise

Abiogen Pharma acquires majority stake in EffRx Switzerland Global Enterprise

FDA Approves Binosto for Osteoporosis - Medical Professionals Reference

FDA Approves Binosto for Osteoporosis Medical Professionals Reference

EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody® in Switzerland - Business Wire

EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody® in Switzerland Business Wire

ABIOGEN PHARMA COMPLETES THE ACQUISITION OF EFFRX - Lelezard

ABIOGEN PHARMA COMPLETES THE ACQUISITION OF EFFRX Lelezard

BINOSTO™ (alendronate sodium), the First and Only Effervescent Tablet and Buffered Oral Solution for the Treatment of Osteoporosis, Provides Alternative to Pill Therapy - CNBC

BINOSTO™ (alendronate sodium), the First and Only Effervescent Tablet and Buffered Oral Solution for the Treatment of Osteoporosis, Provides Alternative to Pill Therapy CNBC

Top Effrx Pharmaceuticals Sa Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant